Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found low- to very low-quality evidence suggesting that several pharmacological treatments, including alpha blockers and antibiotics, may reduce prostatitis symptoms without significantly increasing adverse events in the short term, although more rigorous trials are needed.

This study concluded that five-alpha-reductase inhibitors may reduce prostate cancer risk but could increase the risk of high-grade prostate cancer in men regularly screened for the disease.

This review reports that 100 mg/day spironolactone improved hair growth more than placebo and was more effective in reducing hair growth than finasteride and low-dose cyproterone acetate, but its effectiveness for acne remains unclear due to small sample sizes.

Finasteride can cause one-sided breast enlargement, which disappears after stopping the drug.

This review discusses the role of androgens in menopausal women's health, highlighting symptoms of both hyperandrogenemia and androgen deficiency, but reports no clinical results.

In this study, 23 patients with androgenetic alopecia were treated with non-activated autologous platelet-rich plasma (A-PRP) administered through interfollicular injections, but the abstract provides no results of the treatment's effectiveness.

This review discusses the evidence for using oral medications to treat central serous chorioretinopathy, highlighting eplerenone as having the most support despite a lack of robust efficacy across studies.

This article summarizes the MHRA report on finasteride and does not present new clinical findings.

This case study reports that immunotherapy with ipilimumab and nivolumab induced hypophysitis in a patient with renal cell carcinoma, emphasizing the need for careful monitoring of endocrine function in such treatments.

This study found that autologous platelet-rich plasma treatment significantly increased the number of hairs in male patients with androgenetic alopecia.

Finasteride helped treat a 28-year-old's facial skin condition.

This article reviews the clinical features, diagnostic criteria, and possible genetic and environmental influences of polycystic ovary syndrome but provides no new research findings.

This review discusses the role of DHEA in intracrinology, highlighting its impact on breast and prostate cancer treatment and potential as a menopause therapy, but reports no new research findings.

In this study, 96% of men with persistent sexual side effects from finasteride reported continued dysfunction after discontinuation, suggesting these effects may endure long-term.

This article discusses treatment options for androgenetic alopecia, noting that medical interventions like finasteride and minoxidil can halt and partially reverse hair loss in mild to moderate cases, especially when combined with surgery.

This review summarizes the application of microneedles in treating various skin diseases and highlights challenges like low drug loading, noting no new clinical results are reported.

This study found that finasteride at 1 mg/day was the most effective dose for treating male pattern hair loss, with similar efficacy to 5 mg/day and better results than lower doses.

This study found that in Japanese male patients with androgenetic alopecia, dutasteride 0.5 mg daily over 52 weeks was associated with improvements in hair growth and appearance, with reported adverse events mostly mild.

This study suggests that gender-affirming testosterone therapy in transgender men is generally safe and effective with adequate screening and monitoring, although high-quality long-term studies are lacking.

This review presents substantial evidence supporting testosterone use for hypoactive sexual desire disorder in postmenopausal women, but notes safety concerns with off-label prescribing due to lack of approved formulations.

The document concludes that using LC-MS/MS for measuring androgens is more accurate than older methods, but it needs careful validation and standardized references to be most effective.

This review describes current medical and surgical treatments for transgender men, highlighting the effectiveness and general tolerability of hormone treatment, and suggesting that surgical benefits often surpass associated risks, although it reports no new clinical findings.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

This article updates the process of care model for evaluating erectile dysfunction, emphasizing comprehensive evaluation and a combination of pharmacotherapy and counseling tailored to patient dynamics.

This review discusses the physiology and potential hormonal mechanisms involved in female pattern hair loss, as well as the current hormonal and hormone-modifying treatments available, but reports no new research findings.

This review discusses cross-sex hormone therapy for managing gender dysphoria in transsexual individuals and reports no new clinical results; it highlights the need for education and culturally sensitive training for healthcare professionals.

This review discusses diagnostic criteria for polycystic ovary syndrome and highlights the challenges and risks of misdiagnosing women with other hyperandrogenism causes; it reports no clinical results.

The authors reviewed the mechanisms behind Kennedy's disease, noting advances in therapeutic strategies such as androgen deprivation and gene silencing that may soon expand treatment options for this incurable neuromuscular condition.

This study found that surgical normalization of testosterone in hyperandrogenic women with ovarian androgen-secreting tumors did not significantly change body weight or insulin sensitivity after 12 months.

This review discusses post-finasteride syndrome, characterized by persistent symptoms despite discontinuation, and concludes that its existence cannot be confirmed; individualized assessment is advisable for those with a history of depression, sexual dysfunction, or infertility.